CLOSING THE DIAGNOSTIC GAP IN OVARIAN CANCER DETECTION
With
Associate Professor Michelle Hill
Founder and CEO
ProSeek bio
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane & Sydney | May 2026
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.
ProSeek bio is developing a non-invasive blood test designed to help clinicians determine whether surgery is truly necessary. Using advanced glycoproteomics to detect ovarian cancer biomarkers in blood, the technology is being developed to deliver more precise diagnostic insights through blood sample processed in existing pathology laboratories.
The goal is clear: enable earlier diagnosis, reduce unnecessary surgeries, lower healthcare costs and improve survival outcomes for women.
Ovarian cancer remains the most lethal women’s cancer because symptoms are often vague, common and easily overlooked. Bloating, pelvic pain and unexplained weight changes are frequently dismissed, contributing to delayed diagnosis in more than 70% of cases. Yet when ovarian cancer is detected early, more than 90% of women survive at least five years. When diagnosed late, survival drops dramatically.
ProSeek bio was founded to change that reality.
Built on more than a decade of biomarker research, the company is translating academic discovery into a clinical diagnostic tool with the potential to transform how ovarian cancer is detected and managed.
By giving clinicians a faster, safer and less invasive way to assess risk, Assoc Prof Hilll talks about how ProSeek bio is working to change the diagnostic pathway for ovarian cancer — reducing harm, improving decision-making and helping save women’s lives.
Source: Adapted from transcript
Event Credit: Medical Technology Association of Australia (MTAA)
Ovarian cancer statistics credit: Ovarian Cancer Research Foundation (OCRF)
-
App helps Chronic Sleep Deprivation
Earlier this year, Turner Institute for Brain and Mental Health researchers developed SleepSync, the world’s first app that personalises sleep-wake cycles for shift workers to improve their sleep and overall mood.
The research, led by Dr Jade Murray, was published in the journal, Digital Health. Australian Health Journal met with Dr Murray to hear how the application has evolved and been used in personalisation of sleep habits for health care shift workforce.
-
How I Became an Emergency Physician
Dr Kim Hansen was initially attracted to emergency medicine because of its dynamic and chaotic environment. She enjoyed organising the chaos of the emergency department and working with a variety of patients, from newborn babies to centenarians. Dr Hansen found it fulfilling to help people get better or provide them with assistance and guidance when they couldn’t be cured. The unpredictability of the work was also part of the appeal, and she dedicated herself to developing the skills required to be a good emergency doctor.
-
A clinical research career working Sponsor-side, CRO-side to Site-side
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
